SECdecoded Read filings, not jargon.

Quest Diagnostics Inc FY 2025 10-K, explained in plain English

DGX · 10-K for the period ending December 31, 2025, filed February 26, 2026 · Read the original on SEC.gov →

Key financials — as reported

Total revenue$11.0B
Gross margin33.2%
Operating income$1.6B
Net income$992.0M
Diluted EPS$8.75
Cash & equivalents$420.0M
Total assets$16.2B
Long-term debt$5.7B

Key takeaway

Quest Diagnostics reported $11.0 billion in 2025 net revenue, serving about half of U.S. physicians and hospitals and roughly one-third of the adult population annually.

🔒 4 more takeaways in the full analysis

Beneath the surface

Cash of only $420 million against $5.671 billion in long-term debt (fair value ~$5.7 billion) implies a substantial net debt position of over $5.2 billion, a leverage level not obvious from the headline cash figure alone.

🔒 3 more insights a headline reader would miss

This is the free preview. The full analysis explains every line item above and includes 7 more findings — plus insider trades, activist stakes, and 8-K events for DGX.

Read the full analysis free Free account · 5 full analyses included · no card required